AP NEWS

Global Biosimilars Market (2018-2022) to Record a CAGR of Approx 35% - ResearchAndMarkets.com

January 10, 2019

DUBLIN--(BUSINESS WIRE)--Jan 10, 2019--The “Global Biosimilars Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The biosimilars market will register a CAGR of almost 35% by 2022.

Patients and physician’s willingness to switch to biosimilars is expected to drive growth in the market

Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients are very much willing to shift to biosimilars.

Price advantage of biosimilars over biologics

High cost of biologics reduces patient access to these products and increases the total healthcare costs. The reason for less cost of biosimilar can be sue to the smaller number of clinical trials for a biosimilar when compared with original biologic.

Market access barriers for biosimilars

To compete with biologics and to get entry into the market, the biosimilars are facing challenge. The first and foremost challenge is sophisticated manufacturing process associated with biosimilars.

Key Players

Amgen Biogen Merck Novartis Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY APPLICATION

Segmentation by application Comparison by application Oncology and hematology - Market size and forecast 2017-2022 Endocrinology - Market size and forecast 2017-2022 Immunology - Market size and forecast 2017-2022 Nephrology - Market size and forecast 2017-2022 Market opportunity by application

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Americas - Market size and forecast 2017-2022 Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

Patients and physician’s willingness to switch to biosimilars Therapeutic interchangeability regulations for biosimilars across countries Biosimilar “patent dance” Many originator companies entering the biosimilar market

PART 14: VENDOR LANDSCAPE

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors Amgen Biogen Merck Novartis Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/mnmcjt/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190110005295/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biosimilars and Biosuperiors

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/10/2019 06:29 AM/DISC: 01/10/2019 06:29 AM

http://www.businesswire.com/news/home/20190110005295/en

AP RADIO
Update hourly